Cat. No. | Product Name | Species | Expression System |
---|---|---|---|
TMPH-01488 |
HLA-B Protein, Human, Recombinant (E. coli, His)
HLA-B,Human leukocyte antigen |
Human | E. coli |
HLA-B Protein, Human, Recombinant (E. coli, His) is expressed in E. coli expression system with N-6xHis tag. The predicted molecular weight is 38.9 kDa and the accession number is P01889. | |||
TMPH-01496 |
HLA-B Protein, Human, Recombinant (His)
HLA-B |
Human | E. coli |
HLA-B Protein, Human, Recombinant (His) is expressed in E. coli. | |||
TMPK-01424 |
Peptide Ready HLA-E*01:03&B2M Monomer Protein, Human, MHC (His & Avi)
MHC,HLA-E*01:03,Peptide Ready |
Human | HEK293 Cells |
HLA-E*01:03&B2M&Peptide ready Monomer is absent from peptide, namely peptide-receptive MHC. It can be loaded with antigenic peptides matching HLA-E*01:03. Peptide ready MHC molecules comprising human HLA alleles and B2M, which can be readily tetramerized and loaded with peptides of choice in a high-throughput manner. | |||
TMPK-01423 |
Peptide Ready HLA-E*01:03&B2M Monomer Protein, Human, MHC (His & Avi), Biotinylated
MHC,Peptide Ready,HLA-E*01:03 |
Human | HEK293 Cells |
HLA-E*01:03&B2M&Peptide ready Monomer is absent from peptide, namely peptide-receptive MHC. It can be loaded with antigenic peptides matching HLA-E*01:03. Peptide ready MHC molecules comprising human HLA alleles and B2M, which can be readily tetramerized and loaded with peptides of choice in a high-throughput manner. | |||
TMPK-01412 |
HLA-B*15:01&B2M&SARS-CoV-2 epitope (NQKLIANQF) Monomer Protein, Human, MHC (His & Avi)
SARS-CoV-2 epitope,MHC |
Human | HEK293 Cells |
HLA-B*15:01 is strongly associated with asymptomatic infection with SARS-CoV-2 and is likely to be involved in the mechanism underlying early viral clearance. T cells from pre-pandemic individuals carrying HLA-B*15:01 were reactive to the immunodominant SARS-CoV-2 S-derived peptide NQKLIANQF, and 100% of the reactive cells displayed memory phenotype. | |||
TMPK-01545 |
HLA-E*01:03&B2M&Peptide (VMAPRTLVL) Monomer Protein, Human, MHC (His & Avi), Biotinylated
sHLA-E,MHC,MHC class I antigen E,HLAE,MHC ... |
Human | HEK293 Cells |
HLA-E is a nonclassical member of the major histocompatibility complex class I gene locus. HLA-E protein shares a high level of homology with MHC Ia classical proteins: it has similar tertiary structure, associates with β2-microglobulin, and is able to present peptides to cytotoxic lymphocytes. The main function of HLA-E under normal conditions is to present peptides derived from the leader sequences of classical HLA class I proteins, thus serving for monitoring of expression of these molecules ... | |||
TMPK-01416 |
HLA-B*15:01&B2M&SARS-CoV-2 epitope (NQKLIANQF) Monomer Protein, Human, MHC (His & Avi), Biotinylated
MHC,SARS-CoV-2 epitope |
Human | HEK293 Cells |
HLA-B*15:01 is strongly associated with asymptomatic infection with SARS-CoV-2 and is likely to be involved in the mechanism underlying early viral clearance. T cells from pre-pandemic individuals carrying HLA-B*15:01 were reactive to the immunodominant SARS-CoV-2 S-derived peptide NQKLIANQF, and 100% of the reactive cells displayed memory phenotype. | |||
TMPK-01541 |
HLA-E*01:03&B2M&Peptide (VMAPRTLVL) Tetramer Protein, Human, MHC (His & Avi), Biotinylated
QA1,MHC HLA-E alpha-2.1,MHC,HLAE,MHC class... |
Human | HEK293 Cells |
HLA-E is a nonclassical member of the major histocompatibility complex class I gene locus. HLA-E protein shares a high level of homology with MHC Ia classical proteins: it has similar tertiary structure, associates with β2-microglobulin, and is able to present peptides to cytotoxic lymphocytes. The main function of HLA-E under normal conditions is to present peptides derived from the leader sequences of classical HLA class I proteins, thus serving for monitoring of expression of these molecules ... | |||
TMPK-01544 |
HLA-E*01:03&B2M&Peptide (VMAPRTLVL) Tetramer Protein, Human, MHC (His & Avi)
MHC class I antigen E,HLAE,sHLA-E,QA1,MHC ... |
Human | HEK293 Cells |
HLA-E is a nonclassical member of the major histocompatibility complex class I gene locus. HLA-E protein shares a high level of homology with MHC Ia classical proteins: it has similar tertiary structure, associates with β2-microglobulin, and is able to present peptides to cytotoxic lymphocytes. The main function of HLA-E under normal conditions is to present peptides derived from the leader sequences of classical HLA class I proteins, thus serving for monitoring of expression of these molecules ... | |||
TMPK-01452 |
HLA-E*01:03&B2M&Peptide (VMAPKTLVL) Monomer Negative Control Protein, Human, MHC (His & Avi)
HLAE,MHC class I antigen E,MHC,QA1,sHLA-E |
Human | HEK293 Cells |
HLA-E is a nonclassical member of the major histocompatibility complex class I gene locus. HLA-E protein shares a high level of homology with MHC Ia classical proteins: it has similar tertiary structure, associates with β2-microglobulin, and is able to present peptides to cytotoxic lymphocytes. The main function of HLA-E under normal conditions is to present peptides derived from the leader sequences of classical HLA class I proteins, thus serving for monitoring of expression of these molecules ... | |||
TMPK-01514 |
HLA-E*01:03&B2M&Peptide (VMAPRTLVL) Monomer Protein, Human, MHC (His & Avi)
sHLA-E,MHC class I antigen E,MHC HLA-E alp... |
Human | HEK293 Cells |
HLA-E is a nonclassical member of the major histocompatibility complex class I gene locus. HLA-E protein shares a high level of homology with MHC Ia classical proteins: it has similar tertiary structure, associates with β2-microglobulin, and is able to present peptides to cytotoxic lymphocytes. The main function of HLA-E under normal conditions is to present peptides derived from the leader sequences of classical HLA class I proteins, thus serving for monitoring of expression of these molecules ... | |||
TMPK-01413 |
H-2K (b) &B2M&OVA (SIINFEKL) Monomer Protein, Mouse, MHC (His & Avi)
H-2K,OVA,MHC,H2-K1 |
Mouse | HEK293 Cells |
Ovalbumin (OVA) has been historically a popular source of such antigens, since OVA can induce both humoral and cellular immune responses based on well-characterised peptide epitopes. The OVA257-264 octapeptide was one of the frst OVA epitopes to be characterised, it has an amino acid sequence SIINFEKL, which is recognised by cytotoxic T lymphocytes. SIINFEKL forms fbrillar assemblies similar to other peptide hydrogels. Te immunoactive properties of this peptide can therefore be related to its se... | |||
TMPK-01534 |
Chimeric HLA-A*02:01 (mα3) &B2M&LMP2 (CLGGLLTMV) Monomer Protein, Human&Mouse, MHC (His & Avi)
RING12,PSMB9,Proteasome chain 7,RMF,LMP-2,LMP2,MHC,... |
Human & Mouse | HEK293 Cells |
The immunoproteasome, having been linked to neurodegenerative diseases and hematological cancers, has been shown to play an important role in MHC class I antigen presentation. The development of molecular probes that selectively inhibit the major catalytic subunit, LMP2, of the immunoproteasome,LMP2-rich cancer cells compared to LMP2-deficient cancer cells are more sensitive to growth inhibition by the LMP2-specific inhibitor, implicating an important role of LMP2 in regulating cell growth of ma... | |||
TMPK-01523 |
Chimeric HLA-A*02:01 (mα3) &B2M&WT-1 (RMFPNAPYL) Monomer Protein, Human&Mouse, MHC (His & Avi)
WAGR,WT33,AWT1,GUD,RMF,WT1,WIT-2,MHC,NPHS4GUD |
Human & Mouse | HEK293 Cells |
The WT1 protein plays a role in cell growth, the process by which cells mature to perform specific functions (differentiation), and the self-destruction of cells (apoptosis). WT1 is differentially expressed in serous, endometrioid, clear cell, and mucinous carcinomas of the peritoneum, fallopian tube, ovary, and endometrium.The Human HLA-A*0201 WT-1 (RMFPNAPYL) complex Protein is a complex of HLA-A*0201 of the MHC Class I, B2M and RMFPNAPYL peptide of the WT-1. | |||
TMPK-01535 |
Chimeric HLA-A*02:01 (mα3) &B2M&LMP2 (CLGGLLTMV) Tetramer Protein, Human&Mouse, MHC (His & Avi)
Macropain chain 7,LMP2,Proteasome chain 7,RING12,PSMB |
Human & Mouse | HEK293 Cells |
The immunoproteasome, having been linked to neurodegenerative diseases and hematological cancers, has been shown to play an important role in MHC class I antigen presentation. The development of molecular probes that selectively inhibit the major catalytic subunit, LMP2, of the immunoproteasome,LMP2-rich cancer cells compared to LMP2-deficient cancer cells are more sensitive to growth inhibition by the LMP2-specific inhibitor, implicating an important role of LMP2 in regulating cell growth of ma... | |||
TMPK-01522 |
Chimeric HLA-A*02:01 (mα3) &B2M&WT-1 (RMFPNAPYL) Tetramer Protein, Human&Mouse, MHC (His & Avi)
RMF,WT33,WIT-2,MHC,WAGR,AWT1,GUD,WT1,NPHS4GUD |
Human & Mouse | HEK293 Cells |
The WT1 protein plays a role in cell growth, the process by which cells mature to perform specific functions (differentiation), and the self-destruction of cells (apoptosis). WT1 is differentially expressed in serous, endometrioid, clear cell, and mucinous carcinomas of the peritoneum, fallopian tube, ovary, and endometrium.The Human HLA-A*0201 WT-1 (RMFPNAPYL) complex Protein is a complex of HLA-A*0201 of the MHC Class I, B2M and RMFPNAPYL peptide of the WT-1. | |||
TMPK-01418 |
Peptide Ready HLA-G&B2M Monomer Protein, Human, MHC (His & Avi)
MHC,HLA-G,Peptide Ready |
Human | HEK293 Cells |
Peptide Ready HLA-G&B2M Monomer is absent from peptide, namely peptide-receptive MHC. It can be loaded with antigenic peptides matching HLA-G. Peptide ready MHC molecules comprising human HLA alleles and B2M, which can be readily tetramerized and loaded with peptides of choice in a high-throughput manner. | |||
TMPK-01411 |
Peptide Ready HLA-G&B2M Monomer Protein, Human, MHC (His & Avi), Biotinylated
Peptide Ready,HLA-G,MHC |
Human | HEK293 Cells |
Peptide Ready HLA-G&B2M Monomer is absent from peptide, namely peptide-receptive MHC. It can be loaded with antigenic peptides matching HLA-G. Peptide ready MHC molecules comprising human HLA alleles and B2M, which can be readily tetramerized and loaded with peptides of choice in a high-throughput manner. | |||
TMPK-01419 |
Peptide Ready HLA-A*03:01&B2M Monomer Protein, Human, MHC (His & Avi), Biotinylated
MHC,HLA-A*02:01,Peptide Ready |
Human | HEK293 Cells |
Peptide Ready HLA-A*03:01&B2M Monomer is absent from peptide, namely peptide-receptive MHC. It can be loaded with antigenic peptides matching HLA-A*03:01. Peptide ready MHC molecules comprising human HLA alleles and B2M, which can be readily tetramerized and loaded with peptides of choice in a high-throughput manner. | |||
TMPK-01426 |
Peptide Ready HLA-A*11:01&B2M Monomer Protein, Human, MHC (His & Avi)
HLA-A*02:01,Peptide Ready,MHC |
Human | HEK293 Cells |
Peptide Ready HLA-A*11:01&B2M Monomer is absent from peptide, namely peptide-receptive MHC. It can be loaded with antigenic peptides matching HLA-A*11:01. Peptide ready MHC molecules comprising human HLA alleles and B2M, which can be readily tetramerized and loaded with peptides of choice in a high-throughput manner. | |||
TMPK-01410 |
Peptide Ready HLA-A*24:02&B2M Monomer Protein, Human, MHC (His & Avi)
HLA-A,MHC,Peptide Ready |
Human | HEK293 Cells |
Peptide Ready HLA-G&B2M Monomer is absent from peptide, namely peptide-receptive MHC. It can be loaded with antigenic peptides matching HLA-G. Peptide ready MHC molecules comprising human HLA alleles and B2M, which can be readily tetramerized and loaded with peptides of choice in a high-throughput manner. | |||
TMPK-01422 |
Peptide Ready HLA-A*02:01&B2M Monomer Protein, Human, MHC (His & Avi)
Peptide Ready,MHC,HLA-A*02:01 |
Human | HEK293 Cells |
Peptide Ready HLA-A*02:01&B2M Monomer is absent from peptide, namely peptide-receptive MHC. It can be loaded with antigenic peptides matching HLA-A*02:01. Peptide ready MHC molecules comprising human HLA alleles and B2M, which can be readily tetramerized and loaded with peptides of choice in a high-throughput manner. | |||
TMPK-01425 |
Peptide Ready HLA-A*11:01&B2M Monomer Protein, Human, MHC (His & Avi), Biotinylated
MHC,HLA-A*02:01,Peptide Ready |
Human | HEK293 Cells |
Peptide Ready HLA-A*11:01&B2M Monomer is absent from peptide, namely peptide-receptive MHC. It can be loaded with antigenic peptides matching HLA-A*11:01. Peptide ready MHC molecules comprising human HLA alleles and B2M, which can be readily tetramerized and loaded with peptides of choice in a high-throughput manner. | |||
TMPK-01415 |
APC-equivalent Peptide Ready HLA-A*02:01&B2M Tetramer Protein, Human, MHC (His)
Peptide Ready,HLA-A*02:01,MHC |
Human | HEK293 Cells |
Peptide Ready HLA-A*02:01&B2M Tetramer is absent from peptide, namely peptide-receptive MHC. It can be loaded with antigenic peptides matching HLA-A*02:01. Peptide ready MHC molecules comprising human HLA alleles and B2M, which can be readily tetramerized and loaded with peptides of choice in a high-throughput manner. | |||
TMPK-01409 |
Peptide Ready HLA-A*24:02&B2M Monomer Protein, Human, MHC (His & Avi), Biotinylated
Peptide Ready,MHC,HLA-A |
Human | HEK293 Cells |
Peptide Ready HLA-G&B2M Monomer is absent from peptide, namely peptide-receptive MHC. It can be loaded with antigenic peptides matching HLA-G. Peptide ready MHC molecules comprising human HLA alleles and B2M, which can be readily tetramerized and loaded with peptides of choice in a high-throughput manner. | |||
TMPK-01421 |
Peptide Ready HLA-A*02:01&B2M Monomer Protein, Human, MHC (His & Avi), Biotinylated
HLA-A*02:01,MHC,Peptide Ready |
Human | HEK293 Cells |
HLA-A*02:01&B2M&Peptide ready Monomer is absent from peptide, namely peptide-receptive MHC. It can be loaded with antigenic peptides matching HLA-A*02:01. Peptide ready MHC molecules comprising human HLA alleles and B2M, which can be readily tetramerized and loaded with peptides of choice in a high-throughput manner. | |||
TMPK-01420 |
Peptide Ready HLA-A*03:01&B2M Monomer Protein, Human, MHC (His & Avi)
Peptide Ready,MHC,HLA-A*02:01 |
Human | HEK293 Cells |
Peptide Ready HLA-A*03:01&B2M Monomer is absent from peptide, namely peptide-receptive MHC. It can be loaded with antigenic peptides matching HLA-A*03:01. Peptide ready MHC molecules comprising human HLA alleles and B2M, which can be readily tetramerized and loaded with peptides of choice in a high-throughput manner. | |||
TMPK-01510 |
HLA-A*03:01&B2M&KRAS WT (VVVGAGGVGK) Tetramer Protein, Human, MHC (His & Avi)
NS,NS3,KRAS2,RASK2,MHC,RALD,K-Ras 2,K-RAS4B,C-K-RAS... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. | |||
TMPK-01463 |
HLA-A*11:01&B2M&KRAS G12C (VVVGACGVGK) Monomer Protein, Human, MHC (His & Avi)
C-K-RAS,KI-RAS,KRAS1,K-RAS4A,KRAS2,CFC2,MHC,NS3,K-RAS2B<... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01429 |
HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi), Biotinylated
MHC,K-Ras 2,NS,K-RAS4A,KRAS,NS3,KI-RAS,K-RAS2A,K-RAS2B |
Human | E. coli |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01500 |
HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQV) Monomer Protein, Human, MHC (His & Avi)
CTAG1,CT6.1,CTAG1B,LAGE2A,MY-ESO-1,LAGE-2,MHC,NY-ES... |
Human | HEK293 Cells |
NY-ESO-1 or New York esophageal squamous cell carcinoma 1 is a well-known cancer-testis antigen (CTAs) with re-expression in numerous cancer types. Its ability to elicit spontaneous humoral and cellular immune responses, together with its restricted expression pattern, have rendered it a good candidate target for cancer immunotherapy. | |||
TMPK-01473 |
HLA-A*24:02&B2M&MAGE-A3 (IMPKAGLLI) Monomer Protein, Human, MHC (His & Avi), Biotinylated
CT1.3,MAGE-3,MZ2-D,MZ2D,HLA-A2402,HLA-A*24... |
Human | HEK293 Cells |
Melanoma antigen gene A3 (MAGE-A3) is one of the most immunogenic cancer testis antigens and is common in various types of cancers. MAGE-A3 can be considered as a predictor for poor prognosis and an option for vaccine immunotherapy in patients with PCa. | |||
TMPK-01518 |
HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Tetramer Protein, Human, MHC (His & Avi)
MHC,NS,KRAS1,K-RAS2A,GTPase Kras,KRAS,RALD,KRAS2,RASK2,C-K-R... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01527 |
HLA-A*03:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer Protein, Human, MHC (His & Avi)
NS,RALD,C-K-RAS,RASK2,K-RAS2B,KRAS2,KRAS,K-RAS2A,K-... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01408 |
HLA-A*02:01&B2M&KRAS G12V (KLVVVGAVGV) Monomer Protein, Human, MHC (His & Avi), Biotinylated
RALD,KRAS1,KRAS2,K-RAS2B,CFC2,NS3,GTPase Kras,MHC,K... |
Human | E. coli |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01433 |
HLA-A*11:01&B2M&KRAS G12C (VVVGACGVGK) Tetramer Protein, Human, MHC (His & Avi)
GTPase Kras,NS3,K-Ras 2,K-RAS2B,RALD,MHC,RASK2,K-RA... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01455 |
HLA-A*02:01&B2M&PRAME (SLLQHLIGL) Monomer Protein, Human, MHC (His & Avi)
OIP4,PRAME,OIP-4,MAPE |
Human | HEK293 Cells |
PRAME (PReferentially expressed Antigen in MElanoma) is a melanoma-associated antigen expressed in cutaneous and ocular melanomas and some other malignant neoplasms, while its expression in normal tissue and benign tumors is limited. | |||
TMPK-01401 |
HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein, Human, MHC (E. coli, His & Avi)
MHC,CFC2,K-Ras 2,RALD,K-RAS4A,NS,RASK2,GTPase Kras,K-RAS2 |
Human | E. coli |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. | |||
TMPK-01488 |
HLA-A*11:01&B2M&KRAS WT (VVVGAGGVGK) Monomer Protein, Human, MHC (His & Avi)
K-RAS4A,MHC,GTPase Kras,K-Ras 2,KRAS2,K-RAS2B,CFC2,... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. | |||
TMPK-01442 |
HLA-A*02:01&B2M&P53 WT (HMTEVVRRC) Tetramer Protein, Human, MHC (His & Avi), PE-Labeled
HLA-A,P53,TP53,LFS1,MHC,BCC7,TRP53,FLJ9294... |
Human | HEK293 Cells |
p53 is a tumor suppressor protein. Under stressful conditions, p53 tightly regulates cell growth by promoting apoptosis and DNA repair. When p53 becomes mutated, it loses its function, resulting in abnormal cell proliferation and tumor progression. Depending on the p53 mutation, it has been shown to form aggregates leading to negative gain of function of the protein. p53 mutant associated aggregation has been observed in several cancer tissues and has been shown to promote tumor growth. | |||
TMPK-01445 |
HLA-A*02:01&B2M&MAGE-A1 (KVLEYVIKV) Monomer Protein, Human, MHC (His & Avi), Biotinylated
CT1.1,MAGE1,MAGE-1,MAGE-A1,MAGE-1 antigen,MAGE A1,MAGE1A,MZ2... |
Human | HEK293 Cells |
MAGE-A1 belongs to the chromosome X-clustered genes of cancer-testis antigen family and is normally expressed in the human germ line but is also overexpressed in various tumors. | |||
TMPK-01477 |
HLA-A*02:01&B2M&AFP (FMNKFIYEI) Monomer Protein, Human, MHC (His & Avi), Biotinylated
HPAFP,FETA,Alpha-1-fetoprotein,AFPD,AFP,Alpha-feto,... |
Human | HEK293 Cells |
Alpha-fetoprotein (AFP), a specific liver cancer marker, T cells expressing AFP-CAR selectively degranulated, released cytokines, and lysed liver cancer cells that were HLA-A*02:01 /AFP while sparing cells from multiple tissue types that were negative for either expressed proteins.CAR T-cell immunotherapy targeting intracellular/secreted solid tumor antigens can elicit a potent antitumor response. | |||
TMPK-01493 |
HLA-A*01:01&B2M&MAGE-A3 (EVDPIGHLY) Tetramer Protein, Human, MHC (His & Avi)
MZ2-D,Melanoma-associated antigen 3,MAGE-3,CT1.3,MZ2D |
Human | HEK293 Cells |
Melanoma antigen gene A3 (MAGE-A3) is one of the most immunogenic cancer testis antigens and is common in various types of cancers. MAGE-A3 can be considered as a predictor for poor prognosis and an option for vaccine immunotherapy in patients with PCa. | |||
TMPK-01458 |
HLA-A*11:01&B2M&KRAS G12A (VVVGAAGVGK) Monomer Protein, Human, MHC (His & Avi)
K-Ras 2,GTPase Kras,KRAS2,MHC,K-RAS4A,CFC2,K-RAS2A,KRAS1,RAS... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01539 |
HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Monomer Protein, Human, MHC (His & Avi), Biotinylated
CTAG1B,CT6.1,MY-ESO-1,LAGE2A,NY-ESO-1,MHC,LAGE-2,ES... |
Human | HEK293 Cells |
NY-ESO-1 or New York esophageal squamous cell carcinoma 1 is a well-known cancer-testis antigen (CTAs) with re-expression in numerous cancer types. Its ability to elicit spontaneous humoral and cellular immune responses, together with its restricted expression pattern, have rendered it a good candidate target for cancer immunotherapy. | |||
TMPK-01451 |
HLA-C 03:04&B2M&KRAS G12D (GADGVGKSAL) Monomer Protein, Human, MHC (His & Avi)
NS3,K-RAS4A,K-Ras 2,NS,KRAS1,RASK2,MHC,KI-RAS,KRAS,CFC2,K-RA... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01529 |
HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer Protein, Human, MHC (His & Avi)
K-RAS4A,KRAS1,MHC,K-RAS2B,CFC2,GTPase Kras,K-RAS4 |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01484 |
HLA-A*02:03&B2M&AFP (FMNKFIYEI) Monomer Protein, Human, MHC (His & Avi)
HPAFP,FETA,AFP,AFPD,Alpha-1-fetoprotein,MHC,Alpha-f... |
Human | HEK293 Cells |
Alpha-fetoprotein (AFP), a specific liver cancer marker, T cells expressing AFP-CAR selectively degranulated, released cytokines, and lysed liver cancer cells that were HLA-A*02:01 /AFP while sparing cells from multiple tissue types that were negative for either expressed proteins.CAR T-cell immunotherapy targeting intracellular/secreted solid tumor antigens can elicit a potent antitumor response. | |||
TMPK-01449 |
HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQC) Monomer Protein, Human, MHC (E. coli, His & Avi)
MHC,CT6.1,CTAG1,LAGE-2,MY-ESO-1,NY-ESO-1,ESO1CTAG,LAGE2A,CTA... |
Human | E. coli |
NY-ESO-1 or New York esophageal squamous cell carcinoma 1 is a well-known cancer-testis antigen (CTAs) with re-expression in numerous cancer types. Its ability to elicit spontaneous humoral and cellular immune responses, together with its restricted expression pattern, have rendered it a good candidate target for cancer immunotherapy. | |||
TMPK-01480 |
HLA-A*02:01&B2M&Survivin (LMLGEFLKL) Monomer Protein, Human, MHC (His & Avi), Biotinylated
IAP4,Survivin,API4,BIRC5,MHC,MHC I,EPR-1,survivin v... |
Human | HEK293 Cells |
Survivin (also known as BIRC5) is an evolutionarily conserved eukaryotic protein that is essential for cell division and can inhibit cell death. Normally it is only expressed in actively proliferating cells, but is upregulated in most, if not all cancers; consequently, it has received significant attention as a potential oncotherapeutic target. | |||
------------------------ 更多 ------------------------ |